<p>在前面的三個月中，16 位分析師對阿卡迪亞醫療保健公司（NASDAQ: ACHC）發佈了評級，呈現出從看漲到看跌的廣泛觀點。</p>
<p>下表總結了他們最近的評級，提供了過去 30 天情緒變化的概覽，並與前幾個月進行了比較。</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看漲</strong></th>
<th align="right"><strong>稍微看漲</strong></th>
<th align="right"><strong>無所謂</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>總評級</strong></td>
<td align="right">4</td>
<td align="right">5</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>過去 30 天</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 個月前</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 個月前</strong></td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 個月前</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>分析師為阿卡迪亞醫療保健公司設定了 12 個月的價格目標，顯示出平均目標為 20.38 美元，最高預估為 30.00 美元，最低預估為 13.00 美元。當前平均價格目標較之前的 25.47 美元下降了 19.98%。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1768420834_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="價格目標圖表" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1768420834_0.png"/></p>
<h2>理解分析師評級：全面解析</h2>
<p>通過對最近分析師行動的深入探討，揭示了阿卡迪亞醫療保健公司在金融專家中的地位。以下總結了關鍵分析師、他們的最新評估以及對評級和價格目標的調整。</p>
<table>
<thead>
<tr>
<th>分析師</th>
<th>分析師公司</th>
<th>採取的行動</th>
<th>評級</th>
<th>當前價格目標</th>
<th>之前價格目標</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>下調</td>
<td>超越大盤</td>
<td>$17.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Ann Hynes</td>
<td>Mizuho</td>
<td>下調</td>
<td>中性</td>
<td>$17.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>下調</td>
<td>同等權重</td>
<td>$14.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>下調</td>
<td>超越大盤</td>
<td>$19.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>下調</td>
<td>中性</td>
<td>$17.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Matthew Gillmor</td>
<td>Keybanc</td>
<td>下調</td>
<td>超配</td>
<td>$25.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>UBS</td>
<td>下調</td>
<td>買入</td>
<td>$24.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Pito Chickering</td>
<td>Deutsche Bank</td>
<td>下調</td>
<td>買入</td>
<td>$20.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Kevin Fischbeck</td>
<td>B of A Securities</td>
<td>下調</td>
<td>遜色於大盤</td>
<td>$13.00</td>
<td>$21.50</td>
</tr>
<tr>
<td>Whit Mayo</td>
<td>Leerink Partners</td>
<td>下調</td>
<td>市場表現</td>
<td>$14.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Matthew Gillmor</td>
<td>Keybanc</td>
<td>下調</td>
<td>超配</td>
<td>$30.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>下調</td>
<td>超越大盤</td>
<td>$22.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Jason Cassorla</td>
<td>Guggenheim</td>
<td>下調</td>
<td>買入</td>
<td>$27.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>UBS</td>
<td>下調</td>
<td>買入</td>
<td>$28.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>下調</td>
<td>中性</td>
<td>$22.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>下調</td>
<td>同等權重</td>
<td>$17.00</td>
<td>$20.00</td>
</tr>
</tbody>
</table>
<h3>關鍵見解：</h3>
<ul>
<li><strong>採取的行動：</strong> 分析師根據市場條件和公司表現調整他們的建議。無論是 ‘維持’、‘上調’ 還是 ‘下調’ 他們的立場，反映了他們對阿卡迪亞醫療保健公司近期發展的反應。這些信息提供了分析師對公司當前狀態的看法快照。</li>
<li><strong>評級：</strong> 深入評估，分析師賦予定性值，從 ‘超越大盤’ 到 ‘遜色於大盤’。這些評級傳達了對阿卡迪亞醫療保健公司相對於更廣泛市場表現的預期。</li>
<li><strong>價格目標：</strong> 深入分析，分析師提供了對阿卡迪亞醫療保健公司股票未來價值的估計。這一分析揭示了分析師預期的變化。</li>
</ul>
<p>理解這些分析師評估與關鍵財務指標相結合，可以為阿卡迪亞醫療保健公司的市場地位提供有價值的見解。保持信息靈通，做出經過深思熟慮的決策，參考我們的評級表。</p>
<p>隨時瞭解阿卡迪亞醫療保健公司的分析師評級。</p>
<p>如果您對跟蹤小型股新聞和表現感興趣，您可以從這裏開始跟蹤。</p>
<h2>發現阿卡迪亞醫療保健公司：更深入的瞭解</h2>
<p>阿卡迪亞醫療保健公司收購和開發行為健康設施。急性住院精神病設施和專業治療設施為阿卡迪亞在美國的收入貢獻了絕大部分。公司的收入來自於為住院精神病和藥物濫用護理、門診精神病護理以及青少年住院治療提供的服務。</p>
<h3>分析阿卡迪亞醫療保健公司的財務表現</h3>
<p><strong>市值分析：</strong> 公司的市值低於行業平均水平，表明其相對於同行較小。這可能由於多種因素，包括被認為的增長潛力或運營規模。</p>
<p><strong>收入增長：</strong> 阿卡迪亞醫療保健公司在過去三個月中表現出積極的結果。截至 2025 年 9 月 30 日，該公司實現了約 <strong>4.41%</strong> 的穩健收入增長率。這表明公司的收入顯著增加。與行業同行相比，該公司的增長率低於醫療保健行業的平均水平。</p>
<p><strong>淨利潤率：</strong> 阿卡迪亞醫療保健公司的淨利潤率超越行業基準，達到 <strong>4.26%</strong>。這表明其成本管理高效，財務健康狀況良好。</p>
<p><strong>股本回報率（ROE）：</strong> 阿卡迪亞醫療保健公司的 ROE 超越行業基準，達到 <strong>1.17%</strong>。這表明其財務管理穩健，股東權益資本的使用效率高。</p>
<p><strong>資產回報率（ROA）：</strong> 公司的 ROA 表現突出，超過行業平均水平。憑藉 <strong>0.57%</strong> 的 ROA，該公司展示了資產的有效利用。</p>
<p><strong>債務管理：</strong> 阿卡迪亞醫療保健公司的債務與股本比率低於行業標準，表明其財務結構穩健，比例為 <strong>0.78</strong>。</p>
<h2>什麼是分析師評級？</h2>
<p>評級來自分析師或銀行和金融系統內的專家，他們針對特定股票或定義的行業進行報告（通常每季度對每隻股票進行一次）。分析師通常從公司電話會議和會議、財務報表以及與重要內部人士的對話中獲取信息，以做出決策。</p>
<p>除了他們的評估外，一些分析師還通過提供關鍵指標的預測，如收益、收入和增長預期，來擴展他們的見解。這些補充信息為交易者提供了進一步的指導。必須認識到，儘管他們是專業人士，分析師仍然是人類，只能根據他們的信念提供預測。</p>
<p>本文由 Benzinga 的自動內容引擎生成，並由編輯審核。</p>

阿卡迪亞醫療保健

<p>在過去三個月中，16 位分析師對阿卡迪亞醫療保健公司（NASDAQ:ACHC）進行了評級，顯示出從看漲到看跌的情緒混合。12 個月的平均目標價為 20.38 美元，低於 25.47 美元，最高為 30.00 美元，最低為 13.00 美元。分析師們調整了他們的評級，許多人因市場條件變化而下調了目標價。阿卡迪亞醫療保健公司的收入增長率為 4.41%，淨利潤率為 4.26%，顯示出強健的財務健康狀況。該公司的債務與股本比率為 0.78，低於行業標準，反映出良好的財務管理</p>

<p>In the preceding three months, 16 analysts have released ratings for Acadia Healthcare Co (NASDAQ: ACHC), presenting a wide array of perspectives from bullish to bearish.</p>
<div class="lb-trans"><p>在前面的三個月中，16 位分析師對阿卡迪亞醫療保健公司（NASDAQ: ACHC）發佈了評級，呈現出從看漲到看跌的廣泛觀點。</p>
</div><p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<div class="lb-trans"><p>下表總結了他們最近的評級，提供了過去 30 天情緒變化的概覽，並與前幾個月進行了比較。</p>
</div><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">4</td>
<td align="right">5</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看漲</strong></th>
<th align="right"><strong>稍微看漲</strong></th>
<th align="right"><strong>無所謂</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>總評級</strong></td>
<td align="right">4</td>
<td align="right">5</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>過去 30 天</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 個月前</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 個月前</strong></td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 個月前</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
</div><p>Analysts have set 12-month price targets for Acadia Healthcare Co, revealing an average target of $20.38, a high estimate of $30.00, and a low estimate of $13.00. Highlighting a 19.98% decrease, the current average has fallen from the previous average price target of $25.47.</p>
<div class="lb-trans"><p>分析師為阿卡迪亞醫療保健公司設定了 12 個月的價格目標，顯示出平均目標為 20.38 美元，最高預估為 30.00 美元，最低預估為 13.00 美元。當前平均價格目標較之前的 25.47 美元下降了 19.98%。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1768420834_0.png" alt="price target chart" original-src="https://www.benzinga.com/files/images/story/2026/1768420834_0.png"/></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<div class="lb-trans"><h2>理解分析師評級：全面解析</h2>
</div><p>The standing of Acadia Healthcare Co among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<div class="lb-trans"><p>通過對最近分析師行動的深入探討，揭示了阿卡迪亞醫療保健公司在金融專家中的地位。以下總結了關鍵分析師、他們的最新評估以及對評級和價格目標的調整。</p>
</div><table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$17.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Ann Hynes</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$17.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$14.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$19.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$17.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Matthew Gillmor</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$25.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$24.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Pito Chickering</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Buy</td>
<td>$20.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Kevin Fischbeck</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$13.00</td>
<td>$21.50</td>
</tr>
<tr>
<td>Whit Mayo</td>
<td>Leerink Partners</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$14.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Matthew Gillmor</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$30.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$22.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Jason Cassorla</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$27.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$28.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$22.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$17.00</td>
<td>$20.00</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>分析師</th>
<th>分析師公司</th>
<th>採取的行動</th>
<th>評級</th>
<th>當前價格目標</th>
<th>之前價格目標</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>下調</td>
<td>超越大盤</td>
<td>$17.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Ann Hynes</td>
<td>Mizuho</td>
<td>下調</td>
<td>中性</td>
<td>$17.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>下調</td>
<td>同等權重</td>
<td>$14.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>下調</td>
<td>超越大盤</td>
<td>$19.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>下調</td>
<td>中性</td>
<td>$17.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Matthew Gillmor</td>
<td>Keybanc</td>
<td>下調</td>
<td>超配</td>
<td>$25.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>UBS</td>
<td>下調</td>
<td>買入</td>
<td>$24.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Pito Chickering</td>
<td>Deutsche Bank</td>
<td>下調</td>
<td>買入</td>
<td>$20.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Kevin Fischbeck</td>
<td>B of A Securities</td>
<td>下調</td>
<td>遜色於大盤</td>
<td>$13.00</td>
<td>$21.50</td>
</tr>
<tr>
<td>Whit Mayo</td>
<td>Leerink Partners</td>
<td>下調</td>
<td>市場表現</td>
<td>$14.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Matthew Gillmor</td>
<td>Keybanc</td>
<td>下調</td>
<td>超配</td>
<td>$30.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>下調</td>
<td>超越大盤</td>
<td>$22.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Jason Cassorla</td>
<td>Guggenheim</td>
<td>下調</td>
<td>買入</td>
<td>$27.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>UBS</td>
<td>下調</td>
<td>買入</td>
<td>$28.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>下調</td>
<td>中性</td>
<td>$22.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>下調</td>
<td>同等權重</td>
<td>$17.00</td>
<td>$20.00</td>
</tr>
</tbody>
</table>
</div><h3>Key Insights:</h3>
<div class="lb-trans"><h3>關鍵見解：</h3>
</div><ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Acadia Healthcare Co. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Acadia Healthcare Co compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Acadia Healthcare Co's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>採取的行動：</strong> 分析師根據市場條件和公司表現調整他們的建議。無論是 ‘維持’、‘上調’ 還是 ‘下調’ 他們的立場，反映了他們對阿卡迪亞醫療保健公司近期發展的反應。這些信息提供了分析師對公司當前狀態的看法快照。</li>
<li><strong>評級：</strong> 深入評估，分析師賦予定性值，從 ‘超越大盤’ 到 ‘遜色於大盤’。這些評級傳達了對阿卡迪亞醫療保健公司相對於更廣泛市場表現的預期。</li>
<li><strong>價格目標：</strong> 深入分析，分析師提供了對阿卡迪亞醫療保健公司股票未來價值的估計。這一分析揭示了分析師預期的變化。</li>
</ul>
</div><p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Acadia Healthcare Co's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<div class="lb-trans"><p>理解這些分析師評估與關鍵財務指標相結合，可以為阿卡迪亞醫療保健公司的市場地位提供有價值的見解。保持信息靈通，做出經過深思熟慮的決策，參考我們的評級表。</p>
</div><p>Stay up to date on Acadia Healthcare Co analyst ratings.</p>
<div class="lb-trans"><p>隨時瞭解阿卡迪亞醫療保健公司的分析師評級。</p>
</div><p>If you are interested in following small-cap stock news and performance you can start by tracking it here.</p>
<div class="lb-trans"><p>如果您對跟蹤小型股新聞和表現感興趣，您可以從這裏開始跟蹤。</p>
</div><h2>Discovering Acadia Healthcare Co: A Closer Look</h2>
<div class="lb-trans"><h2>發現阿卡迪亞醫療保健公司：更深入的瞭解</h2>
</div><p>Acadia Healthcare Co Inc acquires and develops behavioral healthcare facilities. Acute inpatient psychiatric facilities and specialty treatment facilities contribute the vast majority of Acadia's revenue in the United States. The company's revenue is derived from services rendered to patients for inpatient psychiatric and substance abuse care, outpatient psychiatric care, and adolescent residential treatment.</p>
<div class="lb-trans"><p>阿卡迪亞醫療保健公司收購和開發行為健康設施。急性住院精神病設施和專業治療設施為阿卡迪亞在美國的收入貢獻了絕大部分。公司的收入來自於為住院精神病和藥物濫用護理、門診精神病護理以及青少年住院治療提供的服務。</p>
</div><h3>Breaking Down Acadia Healthcare Co's Financial Performance</h3>
<div class="lb-trans"><h3>分析阿卡迪亞醫療保健公司的財務表現</h3>
</div><p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<div class="lb-trans"><p><strong>市值分析：</strong> 公司的市值低於行業平均水平，表明其相對於同行較小。這可能由於多種因素，包括被認為的增長潛力或運營規模。</p>
</div><p><strong>Revenue Growth:</strong> Acadia Healthcare Co displayed positive results in 3M. As of 30 September, 2025, the company achieved a solid revenue growth rate of approximately <strong>4.41%</strong>. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<div class="lb-trans"><p><strong>收入增長：</strong> 阿卡迪亞醫療保健公司在過去三個月中表現出積極的結果。截至 2025 年 9 月 30 日，該公司實現了約 <strong>4.41%</strong> 的穩健收入增長率。這表明公司的收入顯著增加。與行業同行相比，該公司的增長率低於醫療保健行業的平均水平。</p>
</div><p><strong>Net Margin:</strong> Acadia Healthcare Co's net margin excels beyond industry benchmarks, reaching <strong>4.26%</strong>. This signifies efficient cost management and strong financial health.</p>
<div class="lb-trans"><p><strong>淨利潤率：</strong> 阿卡迪亞醫療保健公司的淨利潤率超越行業基準，達到 <strong>4.26%</strong>。這表明其成本管理高效，財務健康狀況良好。</p>
</div><p><strong>Return on Equity (ROE):</strong> Acadia Healthcare Co's ROE excels beyond industry benchmarks, reaching <strong>1.17%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<div class="lb-trans"><p><strong>股本回報率（ROE）：</strong> 阿卡迪亞醫療保健公司的 ROE 超越行業基準，達到 <strong>1.17%</strong>。這表明其財務管理穩健，股東權益資本的使用效率高。</p>
</div><p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>0.57%,</strong> the company showcases effective utilization of assets.</p>
<div class="lb-trans"><p><strong>資產回報率（ROA）：</strong> 公司的 ROA 表現突出，超過行業平均水平。憑藉 <strong>0.57%</strong> 的 ROA，該公司展示了資產的有效利用。</p>
</div><p><strong>Debt Management:</strong> Acadia Healthcare Co's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.78</strong>.</p>
<div class="lb-trans"><p><strong>債務管理：</strong> 阿卡迪亞醫療保健公司的債務與股本比率低於行業標準，表明其財務結構穩健，比例為 <strong>0.78</strong>。</p>
</div><h2>What Are Analyst Ratings?</h2>
<div class="lb-trans"><h2>什麼是分析師評級？</h2>
</div><p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<div class="lb-trans"><p>評級來自分析師或銀行和金融系統內的專家，他們針對特定股票或定義的行業進行報告（通常每季度對每隻股票進行一次）。分析師通常從公司電話會議和會議、財務報表以及與重要內部人士的對話中獲取信息，以做出決策。</p>
</div><p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<div class="lb-trans"><p>除了他們的評估外，一些分析師還通過提供關鍵指標的預測，如收益、收入和增長預期，來擴展他們的見解。這些補充信息為交易者提供了進一步的指導。必須認識到，儘管他們是專業人士，分析師仍然是人類，只能根據他們的信念提供預測。</p>
</div><p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>
<div class="lb-trans"><p>本文由 Benzinga 的自動內容引擎生成，並由編輯審核。</p>
</div>

阿卡迪亞醫療保健公司股票：深入分析分析師觀點（16 個評級）